文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

银屑病:局部和全身治疗的最新进展

Psoriasis: an update on topical and systemic therapies.

作者信息

Chan Jonathan J

机构信息

Sir Charles Gairdner Hospital, Perth.

The University of Western Australia, Perth.

出版信息

Aust Prescr. 2025 Jun;48(3):87-92. doi: 10.18773/austprescr.2025.026.


DOI:10.18773/austprescr.2025.026
PMID:40568686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12187478/
Abstract

Psoriasis is an immune-mediated inflammatory disease with a genetic predisposition. Although manifesting predominantly as a hyperproliferative skin disorder, psoriasis is a systemic disease associated with a range of comorbidities including arthritis, cardiovascular disease and depression. Educating the patient that psoriasis is chronic and that there are possible comorbidities is paramount. Patients with a limited number of plaques and no systemic symptoms may be managed with intermittent use of topical therapies. Those with more extensive or debilitating disease may require phototherapy or systemic medicines such as methotrexate or one of the newer targeted therapies. Newer systemic therapies, including oral medicines and injectable biologics, can only be used following unsuccessful treatment with traditional therapies such as methotrexate and phototherapy. Biologic therapies for psoriasis offer the possibility of near-complete symptom resolution in people with psoriatic disease.

摘要

银屑病是一种具有遗传易感性的免疫介导性炎症性疾病。虽然银屑病主要表现为一种皮肤过度增殖性疾病,但它是一种与一系列合并症相关的全身性疾病,这些合并症包括关节炎、心血管疾病和抑郁症。告知患者银屑病是慢性疾病且可能存在合并症至关重要。皮损数量有限且无全身症状的患者可通过间歇性使用外用疗法进行治疗。那些病情更广泛或更严重的患者可能需要光疗或系统性药物,如甲氨蝶呤或一种新型靶向疗法。新型系统性疗法,包括口服药物和注射用生物制剂,只有在使用甲氨蝶呤和光疗等传统疗法治疗失败后才能使用。银屑病的生物疗法为银屑病患者提供了几乎完全缓解症状的可能性。

相似文献

[1]
Psoriasis: an update on topical and systemic therapies.

Aust Prescr. 2025-6

[2]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[3]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[4]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2017-12-22

[5]
[Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology].

Ann Dermatol Venereol. 2010-1

[6]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2022-5-23

[7]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[8]
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Health Technol Assess. 2006-11

[9]
Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.

J Manag Care Pharm. 2012

[10]
Risk of herpes zoster and postherpetic neuralgia in patients with psoriasis treated with biologics: a nationwide study using a target trial emulation framework.

Br J Dermatol. 2025-6-20

本文引用的文献

[1]
Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development.

Rheumatology (Oxford). 2025-3-1

[2]
Skin Cancer Risk of Narrow-Band UV-B (TL-01) Phototherapy: A Multi-Center Registry Study with 4,815 Patients.

Acta Derm Venereol. 2024-4-17

[3]
Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia.

Australas J Dermatol. 2023-11

[4]
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients.

Australas J Dermatol. 2023-11

[5]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2023-7-12

[6]
Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.

Ann Pharmacother. 2024-4

[7]
Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients.

Life (Basel). 2023-5-19

[8]
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.

J Eur Acad Dermatol Venereol. 2022-6

[9]
Depression and Suicidality in Patients With Psoriasis and the Role of Psoriatic Arthritis: A Cross-sectional Study in a Tertiary Setting.

J Acad Consult Liaison Psychiatry. 2022

[10]
Nutritional Therapy in Persons Suffering from Psoriasis.

Nutrients. 2021-12-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索